Stock Analysis
Repligen CorpRGEN
P/E 238.33×· not meaningful — TTM earnings temporarily depressed
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsStrong Buy28 analystsPrice is 79% of the way from the year's low to its high.
Cash covers 117% of debt · Q2 2026.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Quality92
- Financial Health78
Risks
- Growth31
- Profitability35
Mixed picture — no clear quality or value edge.
Market context
-4.8% today· Z 1.4σ
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Altman Z 7.9 — safe-zone balance sheet
What's happening with RGEN
Profile
Strong earnings quality and financial health; valuation, growth and profitability lag behind.
How is each axis scored?
- Valuation10/100 · Weak
- P/E vs own history (80th pct)0/25
- FCF yield (1.0%)5/25
- P/S (14.2x)5/25
- EV/EBIT (170.6x)0/25
- Growth31/100 · Weak
- Revenue CAGR (2.4%)6/25
- Net income CAGR (-21.4%)0/25
- EPS CAGR 5Y (-21.2%)0/25
- Fwd implied growth (216.6%)25/25
- Profitability35/100 · Weak
- ROIC (2.6%)5/25
- ROE (2.0%)5/25
- Net margin (5.3%)13/25
- Operating margin (8.2%)12/25
- Financial Health78/100 · Strong
- Altman Z (7.94)25/25
- Current ratio (9.05)25/25
- Interest coverage (1.7x)3/25
- Net cash / debt (Net cash)25/25
- Quality92/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-2.55)25/25
- FCF conversion (270%)25/25
- Margin stability (σ 7.4%)20/25
- Moat55/100 · Moderate
- ROIC >12% years (1/10 yrs)0/25
- Median gross margin (55.2%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst -4.0%)5/25
Risk Flags
- ⚠Interest coverage 1.7× — thin debt cushion
About Repligen Corp
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Show more
Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Headquarters: WALTHAM, MA · Employees: 2,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
10EP/E (TTM)238xC
Grade C: DistortedTTM earnings are temporarily depressed — this multiple overstates expensiveness. Forward P/E is a better guide — vs own 5Y history: 0.0x–5606.0x · 80th pct
P/FCF105.9xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield1.0%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 0.2%–2.0% · 48th pct
P/S (TTM)14.19xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 7.6x–34.3x · 44th pct
EV/EBIT170.6xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 28.7x–611.0x · 51st pct
EV/Sales14.8xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E75.3xD
Grade D: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio5.27xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio11.27D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
35DROIC2.6%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE2.0%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA1.4%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin5.3%C
Grade C: AverageNet Income / Revenue
Operating Margin8.2%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin53.8%A
Grade A: PremiumGross Profit / Revenue
FCF Margin14.3%C
Grade C: AverageFCF / Revenue
True FCF Margin10.0%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
31DRevenue CAGR2.4%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-21.4%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-21.2%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth216.6%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-0.7%B
Grade B: FlatShare count change over 5Y
SBC / Net Income80.1%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue4.2%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
78B+Altman Z-Score7.94A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio9.05xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio7.30xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage1.7xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.33xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt1.17xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
92A+Piotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.55A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion269.5%A
Grade A: StrongFCF / Net Income
Margin Stability7.4%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue2.9%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.27xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Douglass Brian Robb Filed | Douglass Brian Robb | Grant / award | +675 | |
Douglass Brian Robb Filed | Douglass Brian Robb | Grant / award | +700 | |
Loeillot Olivier Filed | Loeillot Olivier | Option exercise | -4202 | |
Loeillot Olivier Filed | Loeillot Olivier | SellOpen market sale | -4202 | |
Loeillot Olivier Filed | Loeillot Olivier | Option exercise | +4.2K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Loeillot Olivier Filed | Loeillot Olivier | SellOpen market sale | -1333 | |
Loeillot Olivier Filed | Loeillot Olivier | Tax withholding | -1248 | |
Garland Jason K Filed | Garland Jason K | Tax withholding | -421 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
55CROIC >12% Years1/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)55.2%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-4.0%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$0.74
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$14.36
Cash & short-term investments per share (Finnhub)
Book Value / Share$37.43
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$690.94M
Total debt obligations (short + long term)
Cash & Equiv.$810.45M
Cash and short-term investments
Net Debt$-119.51MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$2.11B
Shareholders' equity (book value)
Asset / Liability3.52xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$11.14B
Current Market Capitalization
Beta1.13B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Repligen Corp (RGEN)
RGEN is down 4.75% at the last close. Repligen Corp meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 7.94 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.55 suggests a low likelihood of earnings manipulation.
- Company is effectively debt-free after netting cash.
- Interest coverage of 1.7× leaves little room for earnings shocks.
- Repligen Corp posted a net loss in 1 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 10/100, RGEN trades at a premium to its historical multiples (P/E 238.3).
See how RGEN ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all RGEN moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 6 | Regular | 174.92 | -7.69% | -3.11 |
| Oct 6 | After-hours | 174.84 | -7.74% | -3.13 |
| Oct 1 | Regular | 179.76 | -6.49% | -3.83 |
Frequently Asked Questions about RGEN
What is the current Repligen Corp (RGEN) stock price?
RGEN is trading at $175.42 at the last market close, down 4.75% on the session. PreMarketPrice tracks RGEN pre-market, intraday and after-hours prices.
Is RGEN stock a buy right now?
PreMarketPrice's quantitative model rates Repligen Corp's financial health at 78/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is RGEN stock overvalued?
Repligen Corp trades at a trailing P/E of 238.3 and our valuation score rates it 10/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Repligen Corp report earnings?
No confirmed earnings date is currently scheduled for RGEN. The Earnings section lists recent reports and updates as dates are announced.
What sector does Repligen Corp operate in?
Repligen Corp operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Repligen Corp do?
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies.
About Repligen Corp (RGEN) Stock
Repligen Corp (RGEN) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. As of the latest update, Repligen Corp is trading at $175.42, down 4.75% on the day with a market capitalization of $11.1 billion. The financial health score for RGEN is 78/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for RGEN stock.
RGEN Stock Analysis & Key Metrics
On PreMarketPrice, you can track Repligen Corp (RGEN) across multiple dimensions:
- Pre-market price & movement: Real-time RGEN stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for RGEN with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Repligen Corp across multiple reporting periods.
- Financial health score: A composite score of 78/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for RGEN.
- Sector peers: Compare RGEN against 5 other healthcare stocks on key financial metrics.
Is RGEN a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Repligen Corp (RGEN) as an investment. The financial health score of 78/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Repligen Corp (RGEN) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.